As Bayer preps for its slim-down, a restructuring looms–but jobs are safe, CEO says

Carly Helfand

As moves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a is afoot, the company said Wednesday. But it's one that won't cost the drugmaker any staff positions.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS